Zero Candida Begins Trading on OTCQB Market, Expanding Reach in Women's Health

Zero Candida Launches Trading on OTCQB Market

On March 12, 2025, Zero Candida Technologies, Inc. (TSXV: ZCT) made a significant stride in its operations by commencing trading on the OTCQB Venture Market, indicating a promising future for the FemTech medical device company. This move will allow the company to broaden its international market presence while continuing to trade on both the TSX Venture Exchange and the Frankfurt Stock Exchange.

Eli Ben Haroosh, the company's founder and CEO, expressed excitement about this milestone, highlighting it as a critical point in Zero Candida's long-term growth strategy. He emphasized the company’s goal of expanding its investor base to further fuel its mission of advancing women's health through innovative AI technologies. The timing of this listing aligns perfectly with Zero Candida's recent advancements in patenting, alongside tapping into the expanding market for Vulvo-Vaginal Candidiasis (VVC) treatment. With a staggering 75% of women experiencing VVC at some point in their lives and recurrent cases becoming harder to treat with conventional medicine, Zero Candida stands at the forefront of addressing this critical health issue.

The OTCQB, managed by the OTC Markets Group, is recognized by the U.S. SEC and is seen as a reputable marketplace for startups and developmental-stage firms, enhancing liquidity and visibility for its listed companies. To maintain this esteemed listing, Zero Candida must adhere to stringent financial reporting standards and undergo an annual verification process, which showcases its commitment to transparency and sound business practices.

Zero Candida is leading the charge to innovate treatment for VVC with its novel device that utilizes artificial intelligence and therapeutic blue light. This device, which resembles a traditional tampon, offers a precise treatment to combat Candida fungus, boasting an impressive success rate of 99.999% in point-of-care environments. This groundbreaking solution is not only user-friendly but also aims to significantly improve the quality of life for women affected by VVC, particularly those who experience frequent recurrences.

Currently, recurrent Candidiasis cases exhibit a troubling rising trend, with many treatments proving ineffective due to a lack of understanding of the underlying causes. In light of this public health challenge, Zero Candida's device stands as a beacon of hope, embarking on a regulatory pathway to secure FDA approval. With successful safety trials conducted in large animal models, the company is gearing up for human trials and anticipates a robust response to its innovative approach.

Furthermore, Zero Candida has established partnerships with leading European and Israeli hospitals, strengthening its research and development capabilities while also expanding its patent portfolio across multiple countries. Notably, applications are now filed in major markets including the United States, Brazil, and Europe, complementing its already robust patent protection in South Africa.

As the VVC market is projected to reach $2 billion within the next five years, Zero Candida is positioning itself as a pivotal player through the convergence of advanced medical technology and hybrid medicine. The organization's mission is to improve access to essential healthcare services for underserved populations, ensuring that gynecological care is not only forward-thinking but also accessible.

In conclusion, the commencement of trading on the OTCQB is just the beginning for Zero Candida Technologies, Inc. As the company prepares to unleash the potential of its innovative health solutions, the future looks promising for women's health and wellness. For more updates on Zero Candida’s advancements, watch their latest video detailing the $2 billion market opportunity and their plans for expanding global reach through innovative AI solutions in women's health.